[go: up one dir, main page]

YU20600A - Nova upotreba antagonista 5-ht3 receptora - Google Patents

Nova upotreba antagonista 5-ht3 receptora

Info

Publication number
YU20600A
YU20600A YU20600A YU20600A YU20600A YU 20600 A YU20600 A YU 20600A YU 20600 A YU20600 A YU 20600A YU 20600 A YU20600 A YU 20600A YU 20600 A YU20600 A YU 20600A
Authority
YU
Yugoslavia
Prior art keywords
relates
receptor
treatment
receptor antagonists
ibs patients
Prior art date
Application number
YU20600A
Other languages
English (en)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU20600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU20600A publication Critical patent/YU20600A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na upotrebu antagonista 5-HT3 receptora u proizvodnji medikamenta za tretiranje IBS kod ženskih pacijenata koji ne pate od zatvora. Antagonisti 5-TH3 receptora koji su obuhvaćeni ovim pronalaskom izabrani su iz grupe koju čini alosetron, granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacorpide, cilansetron, itasetron, indisetron ili dolasetron.[This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
YU20600A 1997-10-07 1998-10-05 Nova upotreba antagonista 5-ht3 receptora YU20600A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments

Publications (1)

Publication Number Publication Date
YU20600A true YU20600A (sh) 2003-10-31

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20600A YU20600A (sh) 1997-10-07 1998-10-05 Nova upotreba antagonista 5-ht3 receptora

Country Status (36)

Country Link
US (3) US6284770B1 (sh)
EP (1) EP1021174A2 (sh)
JP (1) JP2001518495A (sh)
KR (1) KR20010015707A (sh)
CN (1) CN1281357A (sh)
AP (1) AP2000001785A0 (sh)
AR (1) AR017296A1 (sh)
AU (1) AU750818B2 (sh)
BR (1) BR9812886A (sh)
CA (1) CA2305751A1 (sh)
CO (1) CO5011096A1 (sh)
DZ (1) DZ2618A1 (sh)
EA (1) EA003184B1 (sh)
EE (1) EE200000214A (sh)
GB (1) GB9721139D0 (sh)
GT (1) GT199800157A (sh)
HN (1) HN1998000155A (sh)
HR (1) HRP20000198A2 (sh)
HU (1) HUP0003750A3 (sh)
ID (1) ID23874A (sh)
IL (1) IL135398A0 (sh)
IS (1) IS5425A (sh)
MA (1) MA26549A1 (sh)
NO (1) NO20001776L (sh)
NZ (1) NZ503698A (sh)
PA (1) PA8461101A1 (sh)
PE (1) PE120299A1 (sh)
PL (1) PL340337A1 (sh)
SK (1) SK4862000A3 (sh)
SV (1) SV1998000122A (sh)
TN (1) TNSN98179A1 (sh)
TR (1) TR200000913T2 (sh)
UY (1) UY25200A1 (sh)
WO (1) WO1999017755A2 (sh)
YU (1) YU20600A (sh)
ZA (1) ZA989061B (sh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
AU2001288564A1 (en) * 2000-09-06 2002-03-22 Glaxo Group Limited 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
PT2266558T (pt) * 2001-06-07 2017-07-21 Analgesic Neuropharmaceuticals Llc Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
ES2281646T3 (es) * 2002-01-18 2007-10-01 Aryx Therapeutics Antagonistas del receptor 5-ht3 y procedimientos de utilizacion.
DE60326585D1 (de) * 2002-07-10 2009-04-23 Dynogen Pharmaceuticals Inc 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
CA2512022A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
CA2550886A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
MXPA05009025A (es) * 2004-01-30 2006-04-27 Astellas Pharma Inc Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.
WO2005076824A2 (en) * 2004-02-03 2005-08-25 The Regents Of The University Of California Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1724267B1 (en) * 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
ATE495171T1 (de) * 2005-06-07 2011-01-15 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
CA2642610A1 (en) * 2006-02-20 2007-08-30 Astellas Pharma Inc. Amide derivative or salt thereof
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
MY172676A (en) 2009-03-04 2019-12-10 Liveleaf Inc Method and material for site activated complexing of biologic molecules
JP5836264B2 (ja) 2009-04-29 2015-12-24 ガネーデン バイオテック インコーポレイテッド 不活性化細菌細胞製剤
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
HUE030811T2 (hu) * 2011-10-18 2017-05-29 Helsinn Healthcare Sa Netupitant és palonosetron terápiás kombinációi
KR20200065113A (ko) * 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (en) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0306323B1 (en) * 1987-09-03 1994-09-21 Glaxo Group Limited Lactam derivatives
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
US5116984A (en) 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
EP0566609A1 (en) 1991-01-09 1993-10-27 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
AR017296A1 (es) 2001-09-05
PL340337A1 (en) 2001-01-29
SV1998000122A (es) 1999-07-05
HUP0003750A2 (hu) 2001-10-28
EP1021174A2 (en) 2000-07-26
AU9629398A (en) 1999-04-27
DZ2618A1 (fr) 2003-03-01
EE200000214A (et) 2001-06-15
PA8461101A1 (es) 2000-05-24
GB9721139D0 (en) 1997-12-03
US6284770B1 (en) 2001-09-04
AP2000001785A0 (en) 2000-06-30
GT199800157A (es) 2000-03-30
KR20010015707A (ko) 2001-02-26
CA2305751A1 (en) 1999-04-15
PE120299A1 (es) 1999-12-15
EA200000299A1 (ru) 2000-12-25
BR9812886A (pt) 2000-08-08
TNSN98179A1 (fr) 2005-03-15
US6429209B2 (en) 2002-08-06
WO1999017755A3 (en) 1999-09-23
NZ503698A (en) 2002-10-25
US20010044450A1 (en) 2001-11-22
CO5011096A1 (es) 2001-02-28
WO1999017755A2 (en) 1999-04-15
NO20001776D0 (no) 2000-04-06
HN1998000155A (es) 1999-05-24
IL135398A0 (en) 2001-05-20
US20030036549A1 (en) 2003-02-20
HUP0003750A3 (en) 2003-02-28
EA003184B1 (ru) 2003-02-27
SK4862000A3 (en) 2001-01-18
IS5425A (is) 2000-03-31
ID23874A (id) 2000-05-25
US6593336B2 (en) 2003-07-15
ZA989061B (en) 2001-07-05
NO20001776L (no) 2000-06-06
CN1281357A (zh) 2001-01-24
TR200000913T2 (tr) 2001-01-22
AU750818B2 (en) 2002-07-25
JP2001518495A (ja) 2001-10-16
UY25200A1 (es) 2001-01-31
HRP20000198A2 (en) 2001-04-30
MA26549A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
BG102726A (en) Combined therapy for osteoporosis
MX9805253A (es) Antagonistas del receptor de vitronectina.
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
YU38801A (sh) Azabicikloalkani kao modulatori ccr5
PL366430A1 (en) Sustained release formulations of oxymorphone
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
GB9416442D0 (en) Therapeutic heterocycles
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
GB9818916D0 (en) Use
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
IL132853A0 (en) Combination therapy for modulating the human sexual response
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EP1246619A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
IL139144A0 (en) Mycobacterial inhibitors
MXPA01006319A (es) Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.